Standard Biotools (LAB) Income from Continuing Operations (2010 - 2026)

Standard Biotools (LAB) has 17 years of Income from Continuing Operations data on file, last reported at 14626000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 37.47% year-over-year to 14626000.0 in Q1 2026; TTM through Mar 2026 was 55444000.0, a 76.29% decrease from a year earlier, with the FY2025 full-year figure at 64207000.0, down 162.25% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 14626000.0, down from 8564000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for LAB reached as high as 153196000.0 in Q4 2022 and fell as low as 76288000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 10346882.35 across 5 years, with a median of 21047000.0 in 2023.
• Across the five-year window, Income from Continuing Operations sank 305.96% in 2022 and soared 178.09% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 153196000.0 in 2022, then tumbled by 90.78% to 14126000.0 in 2023, then surged by 178.09% to 39283000.0 in 2024, then tumbled by 78.2% to 8564000.0 in 2025, then slumped by 270.78% to 14626000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 14626000.0 in Q1 2026, 8564000.0 in Q4 2025, and 31700000.0 in Q3 2025.